Log in

Relevant bibliographies by topics / Differentiated thyroid cancers / Journal articles

To see the other types of publications on this topic, follow the link: Differentiated thyroid cancers.

Journal articles on the topic 'Differentiated thyroid cancers'

Author: Grafiati

Published: 7 December 2024

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Differentiated thyroid cancers.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Krause, Kerstin, Stefan Karger, Oliver Gimm, et al. "Characterisation of DEHAL1 expression in thyroid pathologies." European Journal of Endocrinology 156, no. 3 (2007): 295–301. http://dx.doi.org/10.1530/eje-06-0596.

Full text

Abstract:

Iodotyrosine dehalogenase 1 (DEHAL1) is a transmembrane protein involved in the recycling of iodide in the human thyroid. The aim of the present study was (I) to investigate whether DEHAL1 expression is different in differentially functioning thyroid pathologies and (II) to evaluate DEHAL1 as a possible marker of thyroid cell differentiation. Design and methods: Real-time PCR for DEHAL1 and its isoform DEHAL1B was performed in a series of 105 thyroid specimens, including toxic thyroid nodules (TTN), Graves’ disease (GD) thyroids, benign cold thyroid nodules (CTN), normal thyroid tissues and th

APA, Harvard, Vancouver, ISO, and other styles

2

Nix, P., A. Nicolaides, and A. P. Coatesworth. "Thyroid cancer review 2: management of differentiated thyroid cancers." International Journal of Clinical Practice 59, no. 12 (2005): 1459–63. http://dx.doi.org/10.1111/j.1368-5031.2005.00672.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Colevas, A. Dimitrios, and Manisha H. Shah. "Evaluation of Patients with Disseminated or Locoregionally Advanced Thyroid Cancer: A Primer for Medical Oncologists." American Society of Clinical Oncology Educational Book, no. 32 (June 2012): 384–88. http://dx.doi.org/10.14694/edbook_am.2012.32.30.

Full text

Abstract:

Overview: Historically, patients with thyroid cancers are managed by endocrinologists, surgeons and radiation oncologists. Due to recent progress in this field with advances in treatment of thyroid cancer, medical oncologists are now commonly involved in care of patients with advanced thyroid cancers. In this manuscript, we describe general principles in management of patients with various types of thyroid cancers including differentiated, medullary and anaplastic thyroid cancers.

APA, Harvard, Vancouver, ISO, and other styles

4

Vaidya, Abhishek, and Madan Kapre. "Chapter 4: Surgery for Locally Advanced Thyroid Cancers." Journal of Head & Neck Physicians and Surgeons 12, Suppl 1 (2024): S16—S21. http://dx.doi.org/10.4103/jhnps.jhnps_6_24.

Full text

Abstract:

ABSTRACT A small proportion of Differentiated Thyroid Cancers (DTCs) may present with gross tumor extension outside the thyroid, these constitute the locally advanced thyroid cancers. They often carry worse prognosis in terms of local recurrence and disease free survival. The surgical management of these locally advanced thyroid cancers may be challenging. This narrative review provides an overview of the management strategy of such thyroid cancers.

APA, Harvard, Vancouver, ISO, and other styles

5

Hartl, Dana M., Joanne Guerlain, Ingrid Breuskin, et al. "Thyroid Lobectomy for Low to Intermediate Risk Differentiated Thyroid Cancer." Cancers 12, no. 11 (2020): 3282. http://dx.doi.org/10.3390/cancers12113282.

Full text

Abstract:

Many recent publications and guidelines have promoted a “more is less” approach in terms of treatment for low to intermediate risk differentiated thyroid cancer (DTC), which comprise the vast majority of thyroid cancers: less extensive surgery, less radioactive iodine, less or no thyroid hormone suppression, and less frequent or stringent follow-up. Following this approach, thyroid lobectomy has been proposed as a means of decreasing short- and long-term postoperative morbidity while maintaining an excellent prognosis for tumors meeting specific macroscopic and microscopic criteria. This artic

APA, Harvard, Vancouver, ISO, and other styles

6

Min, Seonyoung, and Hyunseok Kang. "What's New in Molecular Targeted Therapies for Thyroid Cancer?" Korean Society for Head and Neck Oncology 37, no. 2 (2021): 1–9. http://dx.doi.org/10.21593/kjhno/2021.37.2.1.

Full text

Abstract:

Thyroid cancer refers to various cancers arising from thyroid gland. Differentiated thyroid cancers (DTCs) include papillary, follicular, and Hurthle cell carcinomas and represent cancers retain normal thyroid functions such as iodine uptake. Radioactive iodine (RAI) is generally used for upfront treatment of metastatic DTCs, but RAI refractory DTCs remain to be clinical challenges. Sorafenib and lenvatinib were approved for the treatment of RAI refractory DTCs and more recently, genomics-based targeted therapies have been developed for NTRK and RET gene fusion-positive DTCs. Poorly differenti

APA, Harvard, Vancouver, ISO, and other styles

7

Iftikhar, Haissan, Mubasher Ikram, Adnan Muhammad, and Karim Nathani. "Unusual Presentation of Differentiated Thyroid Cancer Metastasis." International Archives of Otorhinolaryngology 22, no. 02 (2017): 167–70. http://dx.doi.org/10.1055/s-0037-1604038.

Full text

Abstract:

Introduction The rates of thyroid cancers are on a rise, especially well-differentiated thyroid cancers. This could be partly due to newer diagnostic modalities, like high-resolution ultrasound, that can pick up smaller lesions. Differentiated thyroid cancers with distant metastases are not common, and even rarer is the initial presentation with complaints not related to the neck. Objectives The objective of this series was to study and report the unusual cases of patients with differentiated thyroid cancer with distant metastasis. There is a lack of data in the literature on these cases, and

APA, Harvard, Vancouver, ISO, and other styles

8

Suteau, Valentine, Mathilde Munier, Claire Briet, and Patrice Rodien. "Sex Bias in Differentiated Thyroid Cancer." International Journal of Molecular Sciences 22, no. 23 (2021): 12992. http://dx.doi.org/10.3390/ijms222312992.

Full text

Abstract:

Differentiated thyroid cancers are more frequent in women than in men. These different frequencies may depend on differences in patient’s behavior and in thyroid investigations. However, an impact on sexual hormones is likely, although this has been insufficiently elucidated. Estrogens may increase the production of mutagenic molecules in the thyroid cell and favor the proliferation and invasion of tumoral cells by regulating both the thyrocyte enzymatic machinery and the inflammatory process associated with tumor growth. On the other hand, the worse prognosis of thyroid cancer associated with

APA, Harvard, Vancouver, ISO, and other styles

9

Satapathy, Swayamjeet, and Chandrasekhar Bal. "Chapter 11: Pediatric Differentiated Thyroid Cancers." Journal of Head & Neck Physicians and Surgeons 12, Suppl 1 (2024): S58—S64. http://dx.doi.org/10.4103/jhnps.jhnps_13_24.

Full text

Abstract:

ABSTRACT The document discusses pediatric differentiated thyroid cancer (DTC), focusing on papillary thyroid carcinoma (PTC), which is increasingly prevalent globally, including in India. Despite a more aggressive initial presentation in children, the long-term prognosis is generally positive. Key differences between pediatric and adult DTC are highlighted, such as a higher risk of malignancy in children with thyroid nodules and common RET/PTC gene rearrangements. There is a debate on the age cutoff for defining pediatric DTC, but the document suggests that 18 years is considered appropriate i

APA, Harvard, Vancouver, ISO, and other styles

10

Salehian, Behrouz, Zhong Liu, and Fouad Kandeel. "Genetic Alterations in Differentiated Thyroid Cancers." Endocrine, Metabolic & Immune Disorders - Drug Targets 9, no. 3 (2009): 257–68. http://dx.doi.org/10.2174/187153009789044338.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Busaidy, Naifa Lamki, and Maria E. Cabanillas. "Differentiated Thyroid Cancer: Management of Patients with Radioiodine Nonresponsive Disease." Journal of Thyroid Research 2012 (2012): 1–12. http://dx.doi.org/10.1155/2012/618985.

Full text

Abstract:

Differentiated thyroid carcinoma (papillary and follicular) has a favorable prognosis with an 85% 10-year survival. The patients that recur often require surgery and further radioactive iodine to render them disease-free. Five percent of thyroid cancer patients, however, will eventually succumb to their disease. Metastatic thyroid cancer is treated with radioactive iodine if the metastases are radioiodine avid. Cytotoxic chemotherapies for advanced or metastatic noniodine avid thyroid cancers show no prolonged responses and in general have fallen out of favor. Novel targeted therapies have rec

APA, Harvard, Vancouver, ISO, and other styles

12

FIRAT, Sevde Nur, Işılay TAŞKALDIRAN, Şerife KUŞKONMAZ, and Cavit ÇULHA. "AST/ALT (De Ritis) Ratio in Early Stage Differentiated Thyroid Cancer." Kocaeli Üniversitesi Sağlık Bilimleri Dergisi 8, no. 2 (2022): 125–28. http://dx.doi.org/10.30934/kusbed.1009993.

Full text

Abstract:

Objective: Differentiated thyroid cancers are the most common endocrine cancers and their frequency is increasing with the increase in imaging possibilities. In various malignancies; Even in the absence of liver metastases, it was determined that AST value increased compared to ALT due to increased metabolism, tissue damage and rapid tumor turnover. This rate is known as the De Ritis rate, and in our study, we planned to evaluate whether there is a relationship between histopathological subtype, multifocality, disease stage and risk group and AST/ALT (De Ritis) ratio in early stage thyroid can

APA, Harvard, Vancouver, ISO, and other styles

13

Song, Eyun, Dong Eun Song, Jonghwa Ahn, et al. "Genetic profile of advanced thyroid cancers in relation to distant metastasis." Endocrine-Related Cancer 27, no. 5 (2020): 285–93. http://dx.doi.org/10.1530/erc-19-0452.

Full text

Abstract:

Major clinical challenges exist with differentiated thyroid cancers with distant metastases or rare but aggressive types, such as poorly differentiated thyroid carcinomas and anaplastic thyroid carcinomas. The precise characterization of the mutational profile in these advanced thyroid cancers is crucial. Samples were collected from primary tumors and distant metastases of 64 patients with distant metastases from differentiated thyroid cancer, poorly differentiated thyroid carcinoma, or anaplastic thyroid carcinoma. Targeted next-generation sequencing was performed with 50 known thyroid-cancer

APA, Harvard, Vancouver, ISO, and other styles

14

Pishdad, Reza, and Prasanna Santhanam. "Current and Emerging Radiotracers and Technologies for Detection of Advanced Differentiated Thyroid Cancer: A Narrative Review." Cancers 17, no. 3 (2025): 425. https://doi.org/10.3390/cancers17030425.

Full text

Abstract:

Differentiated thyroid cancer (DTC), which includes papillary and follicular thyroid cancers, differs significantly in pathology compared to other thyroid malignancies such as medullary thyroid cancer (MTC), anaplastic thyroid cancer (ATC), and Hurthle cell carcinoma [...]

APA, Harvard, Vancouver, ISO, and other styles

15

Moon, Jung-Eun, So Won Oh, Ho-Cheol Kang, et al. "Korean Thyroid Association Guidelines on the Management of Differentiated Thyroid Cancers; Part V. Pediatric Differentiated Thyroid Cancer 2024." International Journal of Thyroidology 17, no. 1 (2024): 193–207. http://dx.doi.org/10.11106/ijt.2024.17.1.193.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Hilhorst, Riet, Adrienne van den Berg, Piet Boender, et al. "Differentiating Benign from Malignant Thyroid Tumors by Kinase Activity Profiling and Dabrafenib BRAF V600E Targeting." Cancers 15, no. 18 (2023): 4477. http://dx.doi.org/10.3390/cancers15184477.

Full text

Abstract:

Differentiated non-medullary thyroid cancer (NMTC) can be effectively treated by surgery followed by radioactive iodide therapy. However, a small subset of patients shows recurrence due to a loss of iodide transport, a phenotype frequently associated with BRAF V600E mutations. In theory, this should enable the use of existing targeted therapies specifically designed for BRAF V600E mutations. However, in practice, generic or specific drugs aimed at molecular targets identified by next generation sequencing (NGS) are not always beneficial. Detailed kinase profiling may provide additional informa

APA, Harvard, Vancouver, ISO, and other styles

17

Iñiguez-Ariza, Nicole M., Sina Jasim, Mabel M. Ryder, et al. "Foundation One Genomic Interrogation of Thyroid Cancers in Patients With Metastatic Disease Requiring Systemic Therapy." Journal of Clinical Endocrinology & Metabolism 105, no. 7 (2020): e2346-e2357. http://dx.doi.org/10.1210/clinem/dgaa246.

Full text

Abstract:

Abstract Context Clinical applications of genomic assessment of thyroid cancers are rapidly evolving. Objectives, Design, and Setting We studied tumor samples from patients with imminently threatening and rare thyroid cancers to identify genomic alterations that might correlate with outcomes and/or be productively therapeutically targetable. Patient Context Progressive and metastatic, and/or rare, thyroid cancers were studied, 2012 to 2016, at Mayo Clinic sites. Intervention The intervention was Foundation One tumor interrogation. Main Outcome Measures Main outcome measures included genomic al

APA, Harvard, Vancouver, ISO, and other styles

18

Puttergill, B., S. Khan, I. Christakis, et al. "Thyroid lobectomy for low-risk thyroid cancers." Annals of The Royal College of Surgeons of England 104, no. 2 (2022): 113–16. http://dx.doi.org/10.1308/rcsann.2021.0058.

Full text

Abstract:

Background The 2016 American Thyroid Association (ATA) guidelines proposed thyroid lobectomy for low-risk differentiated thyroid cancer (DTC); however, this approach is yet to be widely adopted. The aim of the study was to review our practice over three years following the publication of these guidelines identifying patients who underwent lobectomy-only for low-risk DTC in two regional units in the same multidisciplinary team (MDT). Method A retrospective review of patients who were operated between January 2016 and December 2018 was carried out. Results In total, 288 patients undergoing thyro

APA, Harvard, Vancouver, ISO, and other styles

19

Nikitski, Alyaksandr V., Marina N. Nikiforova, Linwah Yip, Esra Karslioglu-French, Sally E. Carty, and Yuri E. Nikiforov. "Can TP53-mutant follicular adenoma be a precursor of anaplastic thyroid carcinoma?" Endocrine-Related Cancer 28, no. 9 (2021): 621–30. http://dx.doi.org/10.1530/erc-21-0095.

Full text

Abstract:

Mutations of the TP53 tumor suppressor gene are highly prevalent in thyroid anaplastic carcinomas (AC) but are also reported in some well-differentiated cancers and even in benign adenomas. The natural history of TP53-mutant adenomas and whether they may represent a precursor for well-differentiated cancer or AC is largely unknown. Similarly, the frequency of TP53 mutations in thyroid nodules found on routine molecular analysis of fine-needle aspiration (FNA) samples is not established. A database on 44,510 FNA samples from thyroid nodules with predominantly indeterminate cytology tested using

APA, Harvard, Vancouver, ISO, and other styles

20

Park, Jong-Lyul, Seon-Kyu Kim, Sora Jeon, Chan-Kwon Jung, and Yong-Sung Kim. "MicroRNA Profile for Diagnostic and Prognostic Biomarkers in Thyroid Cancer." Cancers 13, no. 4 (2021): 632. http://dx.doi.org/10.3390/cancers13040632.

Full text

Abstract:

The challenge in managing thyroid nodules is to accurately diagnose the minority of those with malignancy. We aimed to identify diagnostic and prognostic miRNA markers for thyroid nodules. In a discovery cohort, we identified 20 candidate miRNAs to differentiate between noninvasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTP) and papillary thyroid carcinomas (PTC) by using the high-throughput small RNA sequencing method. We then selected three miRNAs (miR-136, miR-21, and miR-127) that were differentially expressed between the PTC follicular variant and other varia

APA, Harvard, Vancouver, ISO, and other styles

21

Shin, Dong Yeob, Ho-Cheol Kang, Sun Wook Kim, et al. "Korean Thyroid Association Guidelines on the Management of Differentiated Thyroid Cancers; Part III. Management of Advanced Differentiated Thyroid Cancers - Chapter 4. Systemic Therapy for Progressive Radioiodine-Refractory Differentiated Thyroid Cancer 2024." International Journal of Thyroidology 17, no. 1 (2024): 168–81. http://dx.doi.org/10.11106/ijt.2024.17.1.168.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Vaidya, Abhishek, and Deepak Sarin. "Chapter 5: Surgery for Neck in Well-differentiated Thyroid Cancers." Journal of Head & Neck Physicians and Surgeons 12, Suppl 1 (2024): S22—S28. http://dx.doi.org/10.4103/jhnps.jhnps_7_24.

Full text

Abstract:

ABSTRACT Thyroid cancers frequently metastasize to neck nodes. However, most of these are occult micrometastases with no impact on survival, while only a small percentage have clinically apparent neck nodes. The impact of nodal metastases on overall survival is very low, as compared to other head-neck sites and pathologies. Hence the surgical management of neck nodes has to be balanced with the likely morbidity of these procedures. This narrative review deals with the management of neck nodal metastasis of well differentiated thyroid cancers.

APA, Harvard, Vancouver, ISO, and other styles

23

Rusinek, Dagmara, Sylwia Szpak-Ulczok, and Barbara Jarzab. "Gene expression profile of human thyroid cancer in relation to its mutational status." Journal of Molecular Endocrinology 47, no. 3 (2011): R91—R103. http://dx.doi.org/10.1530/jme-11-0023.

Full text

Abstract:

This review describes the gene expression profile changes associated with the presence of different mutations that contribute to thyroid cell carcinogenesis. The results are discussed in the context of thyroid cancer biology and of the implications for disease prognosis, while the diagnostic aspect has been omitted. For papillary thyroid cancer (PTC), the most characteristic gene expression profile is associated with the presence ofBRAFmutation. BRAF-associated PTC differ profoundly from RET/PTC or RAS-associated cancers. Simultaneously, they retain many characteristic gene expression features

APA, Harvard, Vancouver, ISO, and other styles

24

Tung, William S., Douglas W. Shevlin, Detlef Bartsch, Jeffrey A. Norton, Samuel A. Wells, and Paul J. Goodfellow. "InfrequentCDKN2 mutation in human differentiated thyroid cancers." Molecular Carcinogenesis 15, no. 1 (1996): 5–10. http://dx.doi.org/10.1002/(sici)1098-2744(199601)15:1<5::aid-mc2>3.0.co;2-k.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Adiwignyo, Dandy Drestanto, Istan Irmansyah Irsan, Satria Pandu Persada Isma, and Nan Bareno Chairus. "Patterns of Bone Metastasis in Breast, Colorectal, and Thyroid Cancers: A Systematic Review." International Journal of Research and Review 12, no. 3 (2025): 391–95. https://doi.org/10.52403/ijrr.20250348.

Full text

Abstract:

Introduction: Bone metastases are a major issue in oncology, causing severe complications like pain, fractures, and reduced quality of life. Different cancers have distinct patterns of metastatic spread, with breast and prostate cancers often affecting bones, while thyroid and colon cancers have more variable tendencies. Understanding these patterns is crucial for guiding diagnostic vigilance and optimizing patient management strategies. Method: This systematic review uses the PRISMA 2020 methodology to search for articles related to bone metastasis sites in stage IV breast, thyroid, and colon

APA, Harvard, Vancouver, ISO, and other styles

26

Cho, Yoon Young, Cho Rok Lee, Ho-Cheol Kang, et al. "Korean Thyroid Association Guidelines on the Management of Differentiated Thyroid Cancers; Part I. Initial Management of Differentiated Thyroid Cancers - Chapter 2. Surgical Management of Thyroid Cancer 2024." International Journal of Thyroidology 17, no. 1 (2024): 30–52. http://dx.doi.org/10.11106/ijt.2024.17.1.30.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Singh, Amandeep, Jeehoon Ham, Joseph William Po, Navin Niles, Tara Roberts, and Cheok Soon Lee. "The Genomic Landscape of Thyroid Cancer Tumourigenesis and Implications for Immunotherapy." Cells 10, no. 5 (2021): 1082. http://dx.doi.org/10.3390/cells10051082.

Full text

Abstract:

Thyroid cancer is the most prevalent endocrine malignancy that comprises mostly indolent differentiated cancers (DTCs) and less frequently aggressive poorly differentiated (PDTC) or anaplastic cancers (ATCs) with high mortality. Utilisation of next-generation sequencing (NGS) and advanced sequencing data analysis can aid in understanding the multi-step progression model in the development of thyroid cancers and their metastatic potential at a molecular level, promoting a targeted approach to further research and development of targeted treatment options including immunotherapy, especially for

APA, Harvard, Vancouver, ISO, and other styles

28

Métayé, Thierry, Pierre Levillain, Jean-Louis Kraimps, and Rémy Perdrisot. "Immunohistochemical detection, regulation and antiproliferative function of G-protein-coupled receptor kinase 2 in thyroid carcinomas." Journal of Endocrinology 198, no. 1 (2008): 101–10. http://dx.doi.org/10.1677/joe-07-0562.

Full text

Abstract:

TSH, via its G-protein-coupled receptor, activates cell growth of both benign and malignant thyroid tumors. G-protein-coupled receptors (GR) kinase 2 (GRK2) has been reported to regulate the TSH receptor but its role in cancer is unknown. To determine a possible function for GRK2 in the growth process of thyroid cancers, we analysed its expression in normal and tumoral thyroid tissues and studied thyroid cancer cell line proliferation after GRK2 overexpression. Thirty one thyroid tissues, including 16 non-medullary thyroid cancers and 15 adjacent normal tissues, were analysed by immunohistoche

APA, Harvard, Vancouver, ISO, and other styles

29

Boudina, Maria, Eleana Zisimopoulou, Persefoni Xirou, and Alexandra Chrisoulidou. "Aggressive Types of Malignant Thyroid Neoplasms." Journal of Clinical Medicine 13, no. 20 (2024): 6119. http://dx.doi.org/10.3390/jcm13206119.

Full text

Abstract:

Differentiated thyroid cancer (DTC) includes many subtypes, which demonstrate favorable to aggressive behavior. During the past decades, efforts have been made to describe aggressive thyroid cancers. Within DTC, aggressive variants constitute rare entities with unique histopathological features and compromised survival, as local and distant metastatic disease is frequent. In recent years, the distinct category of poorly differentiated thyroid cancer was introduced in 2004 and the type of differentiated high-grade thyroid carcinoma was recently added in the 2022 WHO classification of thyroid ne

APA, Harvard, Vancouver, ISO, and other styles

30

Baldet, Line, Jean-Claude Manderscheid, Daniel Glinoer, Claude Jaffiol, Béatrice Coste-Seignovert, and Christine Percheron. "The management of differentiated thyroid cancer in Europe in 1988." Acta Endocrinologica 120, no. 5 (1989): 547–58. http://dx.doi.org/10.1530/acta.0.1200547.

Full text

Abstract:

Abstract. In order to know how thyroid nodules and differentiated thyroid cancers are investigated and treated in 1988, an international inquiry was performed by mean of a questionnaire based on a well-defined case report of a 35-year-old female with a solitary small thyroid nodule. Clinicians were asked to indicate their diagnostic and therapeutic approaches to the reported case and to some variations. Analysis of the 157 responses from thyroid experts showed that three in vitro tests (sensitive-TSH, free T4 and total T4) and three in vivo tests (99mTc or radioiodide scintiscan, fine needle a

APA, Harvard, Vancouver, ISO, and other styles

31

Rao, Smitha S., and Sabaretnam Mayilvaganan. "Immuno-oncology of differentiated thyroid cancer." International Journal of Molecular & Immuno Oncology 6 (May 29, 2021): 72–75. http://dx.doi.org/10.25259/ijmio_36_2020.

Full text

Abstract:

Thyroid cancer has become an epidemic due to easy availability of ultrasound of the neck, and in some countries, routine health checkup ultrasound of neck is routinely done and mandatory. Thyroid cancer detected incidentally and less than 1 cm may warrant only observation, whereas some cancers such as anaplastic thyroid cancer requires urgent intervention. Advances in the field of oncology have been revolutionized by the extensive study of tumor microenvironment (TME). The introduction of immune check point inhibitors resulted in a major shift in the understanding of differentiated thyroid can

APA, Harvard, Vancouver, ISO, and other styles

32

Er Rahali, Yassine, Mustapha Azzakhman, Mohammed Massine El Hammoumi, Jad Isouani, and Ahmed Anass Guerboub. "ANAPLASTIC TRANSFORMATION OF PAPILLARY THYROID CARCINOMA: A RARE BUT FATAL SITUATION(CASE REPORT)." International Journal of Advanced Research 11, no. 02 (2023): 1034–38. http://dx.doi.org/10.21474/ijar01/16340.

Full text

Abstract:

Anaplastic thyroid cancers are the final dedifferentiation form of follicular thyroid tumors. They are one of the most serious cancers with a survival average of 6 months after diagnosis. Many studies suggest that anaplastic thyroid cancers are a form of a pre-existing differentiated thyroid carcinoma, but only a few cases have been reported in the literature. We report the case of a 64-year-old patient, with a 30-year history of a thyroid nodule. He presented a latero cervical swelling with compression signs, evolving for 2 months in a context of general state alteration. The tomodensitometry

APA, Harvard, Vancouver, ISO, and other styles

33

Perveen, Rahima, Jasmin Ferdous, Sharmin Quddus, and Tapati Mandal. "Solitary Liver Metastasis from Follicular Variant Papillary Thyroid Carcinoma: A Case Report." Bangladesh Journal of Nuclear Medicine 22, no. 2 (2021): 146–49. http://dx.doi.org/10.3329/bjnm.v22i2.51768.

Full text

Abstract:

Papillary and follicular thyroid carcinomas, together known as differentiated thyroid carcinomas (DTC), are among the most curable of cancers. Distant metastases are rare events at the onset of DTC. Sites of metastases from follicular thyroid cancer (FTC) are usually osseous, and those from papillary thyroid cancer (PTC) metastasize to regional nodal basins and the lungs. Visceral metastases are rare, but the involvement of multiple sites has been reported so far. Liver metastases from differentiated thyroid carcinoma (LMDTC) are rare.We present the case of a patient with follicular variant of

APA, Harvard, Vancouver, ISO, and other styles

34

Liu, Shirley Yuk Wah, and Enders Kwok Wai Ng. "Robotic versus Open Thyroidectomy for Differentiated Thyroid Cancer: An Evidence-Based Review." International Journal of Endocrinology 2016 (2016): 1–8. http://dx.doi.org/10.1155/2016/4309087.

Full text

Abstract:

While open thyroidectomy (OT) is advocated as the gold standard treatment for differentiated thyroid cancer, the contemporary use of robotic thyroidectomy (RT) is often controversial. Although RT combines the unique benefits of the surgical robot and remote access thyroidectomy, its applicability on cancer patients is challenged by the questionable oncological benefits and safety. This review aims to analyze the current literature evidence in comparing RT to OT on thyroid cancers for their perioperative and oncological outcomes. To date, no randomized controlled trial is available in comparing

APA, Harvard, Vancouver, ISO, and other styles

35

Mills, Jonathan, and William Dalleywater. "Thyroid cancer." InnovAiT: Education and inspiration for general practice 11, no. 4 (2018): 212–17. http://dx.doi.org/10.1177/1755738017752742.

Full text

Abstract:

Thyroid neoplasms represent the most-common endocrine tumour and constitute an extremely varied spectrum of disease. At the most severe end, they may have a very poor prognosis. Malignant thyroid tumours constitute around 1% of cancers and cancer-specific deaths in the UK, with just under 3000 new diagnoses each year and around 350 deaths annually in the UK alone. Although the incidence has doubled over the last 20 years, the mortality rate among men has not changed, although survival rates have improved in women. Thyroid cancer originates from follicular or parafollicular thyroid cells that c

APA, Harvard, Vancouver, ISO, and other styles

36

Poolakkil, Prasanth, Sajith Babu Thavarool, Satheesan Balasubramanyam, and Kandathil Joseph Philip. "De-differentiation in thyroid cancer- an increasingly appreciated concept." International Surgery Journal 8, no. 2 (2021): 757. http://dx.doi.org/10.18203/2349-2902.isj20210400.

Full text

Abstract:

Thyroid cancer is the most common endocrine malignancy. In general, they are said to be of good prognosis, still there are a few aggressive variants. Differentiated carcinomas like papillary and follicular comprise of major proportion and have a less aggressive clinical behaviour, even though some of them tend to be otherwise. De-differentiated and undifferentiated cancers are more aggressive. There has been an already existing theory that these de-differentiated cancers arise from differentiated ones by a process of stepwise molecular changes. There are already reported cases of coexistence o

APA, Harvard, Vancouver, ISO, and other styles

37

Wei, Weijun, Heather Hardin, and Quan-Yong Luo. "Targeting autophagy in thyroid cancers." Endocrine-Related Cancer 26, no. 4 (2019): R181—R194. http://dx.doi.org/10.1530/erc-18-0502.

Full text

Abstract:

Thyroid cancer is one of the most common endocrine malignancies. Although the prognosis for the majority of thyroid cancers is relatively good, patients with metastatic, radioiodine-refractory or anaplastic thyroid cancers have an unfavorable outcome. With the gradual understanding of the oncogenic events in thyroid cancers, molecularly targeted therapy using tyrosine kinase inhibitors (TKIs) is greatly changing the therapeutic landscape of radioiodine-refractory differentiated thyroid cancers (RR-DTCs), but intrinsic and acquired drug resistance, as well as adverse effects, may limit their cl

APA, Harvard, Vancouver, ISO, and other styles

38

Weng, Xun, YangYang, and Yujiao Cai. "Clinical Significance of Circulating Tumor Cells (CTCs) and Survivin on Predicting Prognosis in Thyroid Cancer Patients." Disease Markers 2022 (January 31, 2022): 1–8. http://dx.doi.org/10.1155/2022/5188006.

Full text

Abstract:

Background. Clinical significance of circulating tumor cell (CTC) count, mesenchymal CTCs (MCTCs), and survivin in patients with thyroid cancer remains unclear. We evaluated the relationship between the expression of different CTC subtypes or survivin and the prognosis in patients with thyroid cancer. Patients and Methods. This study enrolled 164 patients with thyroid cancer who were diagnosed from January 2013 to September 2020 in our hospital. Among these patients, there were 73 cases with papillary thyroid cancer (PTC), 60 cases with follicular thyroid cancer (FTC), 12 medullary thyroid can

APA, Harvard, Vancouver, ISO, and other styles

39

Montero-Conde, Cristina, Luis J. Leandro-Garcia, Xu Chen, et al. "Transposon mutagenesis identifies chromatin modifiers cooperating with Ras in thyroid tumorigenesis and detects ATXN7 as a cancer gene." Proceedings of the National Academy of Sciences 114, no. 25 (2017): E4951—E4960. http://dx.doi.org/10.1073/pnas.1702723114.

Full text

Abstract:

Oncogenic RAS mutations are present in 15–30% of thyroid carcinomas. Endogenous expression of mutant Ras is insufficient to initiate thyroid tumorigenesis in murine models, indicating that additional genetic alterations are required. We used Sleeping Beauty (SB) transposon mutagenesis to identify events that cooperate with HrasG12V in thyroid tumor development. Random genomic integration of SB transposons primarily generated loss-of-function events that significantly increased thyroid tumor penetrance in Tpo-Cre/homozygous FR-HrasG12V mice. The thyroid tumors closely phenocopied the histologic

APA, Harvard, Vancouver, ISO, and other styles

40

Woyach, Jennifer A., and Manisha H. Shah. "New therapeutic advances in the management of progressive thyroid cancer." Endocrine-Related Cancer 16, no. 3 (2009): 715–31. http://dx.doi.org/10.1677/erc-08-0335.

Full text

Abstract:

The spectrum of thyroid cancers ranges from one of the most indolent to one of the most aggressive solid tumors identified. Conventional therapies for thyroid cancers are based on the histologic type of thyroid cancers such as papillary or follicular thyroid cancer (differentiated thyroid cancer (DTC)), medullary thyroid cancer (MTC), or anaplastic thyroid cancer (ATC). While surgery is one of the key treatments for all such types of thyroid cancers, additional therapies vary. Effective targeted therapy for DTC is a decades-old practice with systemic therapies of thyroid stimulating hormone su

APA, Harvard, Vancouver, ISO, and other styles

41

Lal, Punita, and Prakash Kumar Swain. "Role of Radiotherapy in Differentiated Thyroid Cancer." World Journal of Endocrine Surgery 5, no. 3 (2013): 71–75. http://dx.doi.org/10.5005/jp-journals-10002-1132.

Full text

Abstract:

ABSTRACT Differentiated thyroid cancers (i.e. papillary or follicular) account for majority of thyroid malignancies. Even though surgery has been the mainstay for these tumors, use of radioactive iodine (I131) therapy and thyroid hormone replacement therapy is common in most of these tumors in adjuvant setting. Radiotherapy is indicated in the presence of, gross residual disease after surgery, extra-capsular extension, and extensive lymph node involvement. As thyroid gland is located at the root of neck, sometimes with retrosternal extension and surrounded by critical structures, it is difficu

APA, Harvard, Vancouver, ISO, and other styles

42

Santiago Carrion, Ada Marie, and Yanerys Agosto-Vargas. "Concurrent Papillary and Follicular Thyroid Cancer Presenting as Shoulder Pain." Journal of the Endocrine Society 5, Supplement_1 (2021): A888. http://dx.doi.org/10.1210/jendso/bvab048.1812.

Full text

Abstract:

Abstract Differentiated thyroid cancer arises from thyroid follicular epithelial cells. It accounts for more than 90% of thyroid cancers. In areas of sufficient iodine nutrition, about 85% of differentiated thyroid cancers are papillary, 10% are follicular and 3% are Hurthle cell carcinomas. The coexistence of different types of thyroid cancer in a single patient is a rare condition. This is the case of a 56 year-old man with medical history of arterial hypertension who presented to clinics with right shoulder pain. Imaging of the right shoulder showed a osteolytic lesion involving the right h

APA, Harvard, Vancouver, ISO, and other styles

43

Ahmadieh, Hala, and Sami T. Azar. "Controversies in the Management and Followup of Differentiated Thyroid Cancer: Beyond the Guidelines." Journal of Thyroid Research 2012 (2012): 1–8. http://dx.doi.org/10.1155/2012/512401.

Full text

Abstract:

Thyroid cancer is among the most common endocrine malignancies. Genetic and environmental factors play an important role in the pathogenesis of differentiated thyroid cancer. Both have good prognosis but with frequent recurrences. Cancer staging is an essential prognostic part of cancer management. There are multiple controversies in the management and followup of differentiated thyroid cancer. Debate still exists with regard to the optimal surgical approach but trends toward a more conservative approach, such as lobectomy, are being more favored, especially in papillary thyroid cancer, of tum

APA, Harvard, Vancouver, ISO, and other styles

44

Kim, Keunyoung, Chae Moon Hong, Ho-Cheol Kang, et al. "Korean Thyroid Association Guidelines on the Management of Differentiated Thyroid Cancers; Part III. Management of Advanced Differentiated Thyroid Cancers - Chapter 3. Radioactive Iodine Therapy in Advanced Thyroid Cancer 2024." International Journal of Thyroidology 17, no. 1 (2024): 153–67. http://dx.doi.org/10.11106/ijt.2024.17.1.153.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Jung, Kyong Yeun, Youngduk Seo, Ho-Cheol Kang, et al. "Korean Thyroid Association Guidelines on the Management of Differentiated Thyroid Cancers; Part III. Management of Advanced Differentiated Thyroid Cancers - Chapter 5. Treatment of Metastatic Lesions in Advanced Differentiated Thyroid Carcinoma 2024." International Journal of Thyroidology 17, no. 1 (2024): 182–87. http://dx.doi.org/10.11106/ijt.2024.17.1.182.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Akhtar, Shabbir, and Haissan Iftikhar. "Extent of thyroidectomy for well-differentiated thyroid cancers." IJS Short Reports 3, no. 1 (2018): 22. http://dx.doi.org/10.4103/ijssr.ijssr_1_18.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Kars, Ayhan, Abdulkadir Sahin, Korhan Kılıc, Muhammed Sedat Sakat, and Arzu Bilen. "Systemic immune inflammation index in differentiated thyroid cancers." Acta Otorhinolaryngologica Italica 42, no. 2 (2022): 150–54. http://dx.doi.org/10.14639/0392-100x-n1665.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Kim, DS, and CJ McCabe. "Novel molecular markers in well-differentiated thyroid cancers." Expert Review of Endocrinology & Metabolism 1, no. 5 (2006): 685–93. http://dx.doi.org/10.1586/17446651.1.5.685.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Nixon, I. J., R. S. Simo, and D. Kim. "Refining definitions within low-risk differentiated thyroid cancers." Clinical Otolaryngology 43, no. 5 (2018): 1195–200. http://dx.doi.org/10.1111/coa.13145.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Hays, M. T., and I. R. McDougall. "CIRCULATING 131-I THYROXINE IN DIFFERENTIATED THYROID CANCERS." Clinical Nuclear Medicine 17, no. 9 (1992): 765. http://dx.doi.org/10.1097/00003072-199209000-00049.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!